-
Product Insights
NewNet Present Value Model: Forte Biosciences Inc’s FB-102
Empower your strategies with our Net Present Value Model: Forte Biosciences Inc's FB-102 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FB-102 in Vitiligo
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FB-102 in Vitiligo report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FB-102 in Vitiligo Drug Details: FB-102 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FB-102 in Graft Versus Host Disease (GVHD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FB-102 in Graft Versus Host Disease (GVHD) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FB-102 in Graft Versus Host Disease (GVHD) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FB-102 in Alopecia Areata
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FB-102 in Alopecia Areata report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FB-102 in Alopecia Areata Drug Details: FB-102 is under development for...
-
Product Insights
NewVaricella Zoster (HHV-3) Infections – Drugs In Development, 2024
Empower your strategies with our Varicella Zoster (HHV-3) Infections – Drugs In Development, 2024 report and make more profitable business decisions. Varicella-zoster virus (VZV), also known as human herpesvirus 3 (HHV-3), causes two distinct infections: chickenpox (varicella) and shingles (herpes zoster). Varicella is a highly contagious viral infection characterized by an itchy rash with red spots and fluid-filled blisters that break open and form scabs. It spreads through respiratory droplets and direct contact with the rash. Varicella commonly affects children, and...
-
Product Insights
NewVitiligo – Drugs In Development, 2024
Empower your strategies with our Vitiligo – Drugs In Development, 2024 report and make more profitable business decisions. Vitiligo is a condition in which skin loses melanin, the pigment that determines the color of skin, hair, and eyes. Symptoms include premature whitening or graying of the hair on teh scalp, eyelashes, eyebrows, or beard; loss of color in the tissues that line the inside of mouth; and loss of or change in color of the inner layer of eye. Treatment includes...
-
Product Insights
NewCeliac Disease – Drugs In Development, 2024
Empower your strategies with our Celiac Disease – Drugs In Development, 2024 report and make more profitable business decisions. Celiac disease is an autoimmune disorder caused by an immune response to wheat protein gluten. Symptoms include weight loss, vomiting, abdominal bloating, abdominal pain, and persistent diarrhea. Risk factors include lupus, rheumatoid arthritis, type 1 diabetes, autoimmune liver disease, Sjogren’s syndrome, and Turner syndrome. Treatment includes steroids such as betamethasone and prednisolone. Treatment also involves adhering to strict gluten-free diet. The Celiac...
-
Product Insights
NewAlopecia Areata – Drugs In Development, 2024
Empower your strategies with our Alopecia Areata – Drugs In Development, 2024 report and make more profitable business decisions. Alopecia areata is an autoimmune condition characterized by unpredictable, patchy hair loss. It occurs when the immune system mistakenly attacks hair follicles, leading to hair loss in small, round patches on the scalp or other parts of the body. In some cases, it can progress to total hair loss (alopecia totalis) or loss of hair on the entire body (alopecia universalis). The...
-
Product Insights
NewAlopecia – Drugs In Development, 2024
Empower your strategies with our Alopecia – Drugs In Development, 2024 report and make more profitable business decisions. Alopecia is the partial or complete loss of hair, especially on the scalp; it can occur in patches, on the entire head, or over the entire body. Thinning hair is the most obvious symptom. The predisposing factors include allergies, exposure to irritants or toxins, burns, injuries, and infections. The Alopecia drugs in development market research report provide comprehensive information on the therapeutics under...
-
Product Insights
NewGraft Versus Host Disease (GVHD) – Drugs In Development, 2024
Empower your strategies with our Graft Versus Host Disease (GVHD) – Drugs In Development, 2024 report and make more profitable business decisions. Graft-versus-host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted donor cells attack the transplant recipient's body. Symptoms include abdominal pain or cramps; nausea, vomiting, and diarrhea; dry or irritated eyes; jaundice; shortness of breath; vaginal dryness; and weight loss. Treatment includes immunosuppressants. The Graft Versus Host...